Glomangiopericytoma: a case series with review of literature

Kazi, Aasif A.; McDougal, Elizabeth M.; Howell, Jessica B.; Schuman, Theodore A.; Nord, Ryan

doi:10.1016/j.bjorl.2021.02.007

Cited by 9 publications

(16 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most studies are in agreement that show strong nuclear expression with β-catenin in virtually all glomangiopericytoma. [8][9][10] Similarly, cyclin D1 was also noted to exhibit nuclear positivity in most (70-100%) of the tumor cells. 8,9 Complete surgical resection is the standard treatment in glomangiopericytoma with radiotherapy reserved only for cases that are inoperable or metastatic.…”

Section: Discussionmentioning

confidence: 92%

“…[8][9][10] Similarly, cyclin D1 was also noted to exhibit nuclear positivity in most (70-100%) of the tumor cells. 8,9 Complete surgical resection is the standard treatment in glomangiopericytoma with radiotherapy reserved only for cases that are inoperable or metastatic. 11 Lymphatic and hematogenous spread of malignant glomangiopericytoma have been reported in 5% of cases and were seen to involve distant organs such tumor stain positively with CD34 and variably with smooth muscle actin.…”

Section: Discussionmentioning

confidence: 92%

See 1 more Smart Citation

Glomangiopericytoma: A Rare Sinonasal Neoplasm

Damian

Alegata²

2022

PJP

View full text Add to dashboard Cite

Glomangiopericytoma is a rare neoplasm of the nasal and paranasal sinuses comprising less than 1% of all tumors of the said region. We report of a 59-year-old hypertensive male who presented with epistaxis. CT scan findings showed a mass in the right nasal cavity with extension into the ethmoid and sphenoid sinuses. Histopathologic diagnosis was glomangiopericytoma confirmed with immunohistochemistry studies. Prognosis is favorable with complete resection of tumor and long-term monitoring.

show abstract

Section: Discussionmentioning

confidence: 92%

Section: Discussionmentioning

confidence: 92%

Glomangiopericytoma: A Rare Sinonasal Neoplasm

Damian

Alegata²

2022

PJP

View full text Add to dashboard Cite

show abstract

“…Overall prognosis is favorable with a 5‐year survival rate of 88% and a recurrence rate of 17%, which change based on complete versus partial resection 1021,1023 . Recurrence has been described to occur up to 12 years later, but most recur within 5 years 1035 . Recurrence is associated with incomplete resection, bony invasion, bilateral involvement, adjuvant chemo/RT, severe nuclear pleomorphism, tumor >5 cm, and high mitotic rate 1022,1023 .…”

Section: Other Rare Benign Neoplasms and Lesionsmentioning

confidence: 99%

International Consensus Statement on Allergy and Rhinology: Sinonasal Tumors

Kuan

Wang

Adappa

et al. 2024

Int Forum Allergy Rhinol

View full text Add to dashboard Cite

BackgroundSinonasal neoplasms, whether benign and malignant, pose a significant challenge to clinicians and represents a model area for multidisciplinary collaboration in order to optimize patient care. The International Consensus Statement on Allergy and Rhinology: Sinonasal Tumors (ICSNT) aims to summarize the best available evidence and presents 48 thematic and histopathology‐based topics spanning the field.MethodsIn accordance with prior ICAR documents, ICSNT assigned each topic as an Evidence‐Based Review with Recommendations, Evidence‐Based Review, and Literature Review based on level of evidence. An international group of multidisciplinary author teams were assembled for the topic reviews using the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses format, and completed sections underwent a thorough and iterative consensus‐building process. The final document underwent rigorous synthesis and review prior to publication.ResultsThe ICNST document consists of 4 major sections: general principles, benign neoplasms and lesions, malignant neoplasms, and quality of life and surveillance. It covers 48 conceptual and/or histopathology‐based topics relevant to sinonasal neoplasms and masses. Topics with a high level of evidence provided specific recommendations, while other areas summarized the current state of evidence. A final section highlights research opportunities and future directions, contributing to advancing knowledge and community intervention.ConclusionAs an embodiment of the multidisciplinary and collaborative model of care in sinonasal neoplasms and masses, ICSNT was designed as a comprehensive, international, and multidisciplinary collaborative endeavor. Its primary objective is to summarize the existing evidence in the field of sinonasal neoplasms and masses.This article is protected by copyright. All rights reserved

show abstract

“…(Park et al 2017) They are rare tumors, comprising less than 0.5% of all sinonasal tumors and considered to have low malignant potential (Stelow and Bishop 2017) but local recurrence and metastasis may occur in a subset of patients, despite complete surgical excision. (Kazi et al 2021) Most of the existing literature on glomangiopericytomas have been limited to single reports or case series, describing clinicopathologic characteristics. Comprehensive genetic study of glomangiopericytomas remains lacking, which may improve criteria for diagnosis and guide adjuvant treatment of surgically refractory tumors.…”

Section: Introductionmentioning

confidence: 99%

“…Glomangioperictyomas, also known as sinonasal hemangioperictyomas, are rare mesenchymal neoplasms with a myoid phenotype, exhibiting positivity for smooth muscle actin (SMA), which distinguishes them from other soft tissue tumors ( Park et al 2017 ). They are rare tumors, comprising <0.5% of all sinonasal tumors and considered to have low malignant potential ( Stelow and Bishop 2017 ), but local recurrence and metastasis may occur in a subset of patients, despite complete surgical excision ( Kazi et al 2021 ). Most of the existing literature on glomangiopericytomas has been limited to single reports or case series, describing clinicopathologic characteristics.…”

Section: Introductionmentioning

confidence: 99%

PIK3CA mutation in a case of CTNNB1-mutant sinonasal glomangiopericytoma

Hong

Khan

Sukys

et al. 2021

Cold Spring Harb Mol Case Stud

View full text Add to dashboard Cite

Glomangiopericytomas are rare, primary sinonasal tumors. The existing literature is mostly limited to reports describing the clinicopathologic characteristics of these tumors. Comprehensive genetic characterization of glomangiopericytomas remain lacking. Whole exome sequencing of a case of glomangiopericytoma was performed under an institutional review board approved protocol. A 69 year-old female underwent surgical resection of a glomangiopericytoma. Whole exome sequencing revealed somatic mutations in CTNNB1 and PIK3CA, the former previously associated with this pathology but the latter not described. Concurrent dysregulation of Wnt/beta-catenin and PI3K/AKT/mTOR signaling, secondary to mutations in these two oncogenes may be amenable to targeted treatment with existing clinically approved drugs. Genomic characterization of glomangiopericytomas remains lacking. This study reports novel co-existence of PIK3CA and CTNNB1 mutations in a case of glomangiopericytoma that may offer insight into the pathogenesis and potential for targeted medical therapies of this rare tumor.

show abstract

Glomangiopericytoma: a case series with review of literature

Cited by 9 publications

References 11 publications

Glomangiopericytoma: A Rare Sinonasal Neoplasm

Glomangiopericytoma: A Rare Sinonasal Neoplasm

International Consensus Statement on Allergy and Rhinology: Sinonasal Tumors

PIK3CA mutation in a case of CTNNB1-mutant sinonasal glomangiopericytoma

Contact Info

Product

Resources

About